Search
Fostemsavir
go.drugbank.com/drugs/DB11796ApprovedInvestigational[L14867] The discovery of gp120 as a potential target of interest in the treatment of HIV-1 infection is relatively recent, and was born out of a desire to find alternative target proteins (i.e. mechanistically … orthogonal therapies) for the treatment of HIV-1 patients with resistant infections.
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseEnzalutamide
go.drugbank.com/drugs/DB08899ApprovedInvestigationalEnzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. … [A252667] Until recently, docetaxel is the only treatment available for metastatic CRPC; however, AR inhibitors have been developed for more targeted therapy, although first-generation AR inhibitors like
Categories: Androgen Receptor Antagonists, Androgen Receptor InhibitorsIndium In-111 chloride
go.drugbank.com/drugs/DB09490Approvedand for radiolabeling Zevalin (ibritumomab tiuxetan) in preparations used for radioimmunotherapy procedures. … Indium In-111 Chloride is a diagnostic radiopharmaceutical agent intended for radiolabeling OncoScint (satumomab pendetide) or ProstaScint (capromab pendetide) used for _in vivo_ diagnostic imaging procedures
Mixtures: OCTREOSCAN FOR INJECTION, OctreoScan - Pulver zur Herstellung einer InjektionslösungCorynebacterium diphtheriae
go.drugbank.com/drugs/DB09877ApprovedInvestigationalCorynebacterium diphtheriae toxin is extracted from the pathogenic actinobacterium C. diphtheriae that causes diphtheria. The bacteria culture is grown in a medium and through purification, diphtheria toxin is detoxified with formaldehyd...
Mixtures: Td-pur für Erwachsene und Heranwachsende, PREVENAR 13 SUSPENSION FOR INJECTIONLofexidine
go.drugbank.com/drugs/DB04948ApprovedInvestigational[T209] Lofexidine was developed by US Woldmeds LLC and it was approved by the FDA on May 16, 2018.[L2794] … [A33084] It was first studied for use as an antihypertensive in 1980, but its researched was stopped as it was found less effective for the treatment of hypertension than clonidine.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesCaptopril
go.drugbank.com/drugs/DB01197ApprovedInvestigationalCaptopril may be used in the treatment of hypertension. … Captopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII).
Categories: P-glycoprotein inhibitors, Antihypertensive Agents Indicated for HypertensionLevoleucovorin
go.drugbank.com/drugs/DB11596ApprovedInvestigationalDespite this difference in activity, the two commercially available forms have been shown to be pharmacokinetically identical and may be used interchangeably with limited differences in efficacy or side … Folic acid is an essential B vitamin required by the body for the synthesis of purines, pyrimidines, and methionine before incorporation into DNA or protein.
Categories: Detoxifying Agents for Antineoplastic TreatmentTumour necrosis factor receptor-associated periodic syndrome
go.drugbank.com/conditions/DBCOND0008484Drugs: CanakinumabSynonyms: TNF-receptor Associated Periodic Syndromes (TRAPS), TNF receptor-associated periodic fever syndromeDaprodustat
go.drugbank.com/drugs/DB11682ApprovedInvestigationalanemia of CKD but not for non-dialysis patients with anemia of CKD. … [A254172] In June 2020, daprodustat was first approved in Japan for the treatment of renal anemia.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 InhibitorsPegcetacoplan
go.drugbank.com/drugs/DB16694ApprovedInvestigational[A235000] Pegcetacoplan for subcutaneous use was granted FDA approval on 14 May 2021. … [A235000,A235005] Pegcetacoplan was developed out of a need for an inhibitor of complement mediated hemolysis further upstream of C5.